申请人:SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
公开号:EP0945426A1
公开(公告)日:1999-09-29
A compound represented by the figure (1) or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders:
wherein Ar is optionally substituted phenyl or optionally substituted heteroaryl;.
n is 0, 1 or 2;
W is -CH2NH- or -CH=N(O)-;
R1, R2 and R3 are independently optionally substituted alkyl, carboxyl or alkoxycarbonyl; any two groups of R1, R2 and R3 may be taken together with the carbon atom to form optionally substituted cycloalkane; all of R1, R2 and R3 may be taken together with the adjusent carbon atom to form optionally substituted bicycloalkane or optionally substituted tricycloalkane;
R4 and R5 are independently hydrogen atom or optionally substituted alkyl.
图(1)所代表的化合物或其药学上可接受的盐可作为治疗视网膜变性疾病的药物:
其中 Ar 是任选取代的苯基或任选取代的杂芳基;.
n 是 0、1 或 2;
W是-CH2NH-或-CH=N(O)-;
R1、R2 和 R3 独立地是任选取代的烷基、羧基或烷氧基羰基;R1、R2 和 R3 中的任意两个基团可与碳原子结合形成任选取代的环烷;所有 R1、R2 和 R3 可与相邻碳原子结合形成任选取代的双环烷或任选取代的三环烷;
R4 和 R5 独立地为氢原子或任选取代的烷基。